Docetaxel for the adjuvant treatment of early breast cancer

Source:
Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA
Publisher:
Centre for Reviews and Dissemination
Publication date:
10 October 2013

Abstract

Bibliographic details

Chilcott J, Lloyd Jones M, Wilkinson A.  Docetaxel for the adjuvant treatment of early breast cancer. Health Technology Assessment 2009; 13 (Suppl 1 Article 2)

Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Indexing status

Subject indexing assigned by NLM

Index terms

Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Breast Neoplasms /drug therapy /economics /pathology; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide /administration & dosage; Doxorubicin /administration & dosage; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Quality of Life; Randomized Controlled Trials as Topic; Taxoids /administration & dosage; Technology Assessment, Biomedical